The modifications of T-lymphocyte cell subpopulations in patients with beta-interferon intracavitary treatment.
18 patients with malignant genital or mammary neoplasia, treated with endocavitary Beta-Interferon (intrapleural or intraperitoneal), were examined in order to study the modifications of T-lymphocyte subpopulations (T3, T4, T8, T4/T8) in the peripheric blood. An improvement in the immune state in complessively 50% of the patients treated was observed, while there were no modifications in the remaining patients (in 3 patients with advanced ovarian cancer there was persistence of immunodepression preexisting to treatment). This indicates that endocavitary Beta-Interferon induced very poor immune response at peripheric level (contrary to what other Authors have described at peritoneal level), correlated to the dose used and to the extent of serous surface exposed to the drug.
Cherchi
P L
PL
Gynaecologic and Obstetric Institute, University of Sassari.
Campiglio
A
A
Rubattu
A
A
Desole
A
A
Andria
G
G
Ambrosini
A
A
D000368:Aged; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D014594:Uterine Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
D007370:Interferon Type I